Usefulness of Carbamazepine in prevention of basilar migraine attack

Efficacy of Carbamazepine in basilar migraine prophylaxis: A clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071380

Enrollment

100

Registered

2024-07-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: G409- Epilepsy, unspecified

Interventions

Intervention1: Carbamazepine in basilar migraine: Minimal doses 200mg once daily carbamazepine to start with in cases of basilar migraine cases who has failed to respond to existing prophylaxis for ne

Eligibility

Inclusion criteria

Inclusion criteria: 1. Fulfilling basilar migraine criteria of the international classification of headache disorder 2. Disabling attack one or more every month

Exclusion criteria

Exclusion criteria: 1. Previous history of drug rashes 2. Clinical evidence of TIA or stroke as well as structural abnormalities on MRI 3. Clinical or EEG evidence of seizure 4. Pregnancy

Design outcomes

Primary

Measure	Time frame
Primary: 1. Decrease in frequency of basilar migraine attacks after 4,12,24 and 48 weeks of therapy •Secondary: 1.Minimal effective doses 2.Decrease in frequency over 01 year 3.Comparison with existing prophylaxis 4.Side effect profileTimepoint: Primary: Decrease in frequency after 4,12,24 & 48 weeks of therapy Secondary: 1.Minimal effective doses 2.Decrease in frequency over 01 year 3.Comparison with existing prophylaxis 4.Side effect profile	—

Measure

Time frame

Primary: 1. Decrease in frequency of basilar migraine attacks after 4,12,24 and 48 weeks of therapy •Secondary: 1.Minimal effective doses 2.Decrease in frequency over 01 year 3.Comparison with existing prophylaxis 4.Side effect profileTimepoint: Primary: Decrease in frequency after 4,12,24 & 48 weeks of therapy Secondary: 1.Minimal effective doses 2.Decrease in frequency over 01 year 3.Comparison with existing prophylaxis 4.Side effect profile

—

Secondary

Measure	Time frame
Secondary: 1.Minimal effective doses 2.Decrease in frequency over 01 year 3.Comparison with existing prophylaxis 4.Side effect profileTimepoint: 01 year	—

Countries

India

Contacts

Public ContactRajeev Ranjan

Command Hospital, Lucknow

captrajeevdoc@gmail.com8806797416

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026